cis-Diamminedichloroplatinum(II) alone and in combination in the treatment of testicular and other malignancies.
A total of 124 patients with malignancy were treated with cis-diamminedichloroplatinum(II) (CDDP) alone (58 patients, 121 courses) or in combination with other drugs (66 patients, 176 courses). Toxic effects of single-agent therapy were primarily nausea and vomiting; mild renal hematopoietic, and auditory toxic effects occasionally occurred. Positive responses were seen in ovarian and testicular tumors. Rare responses were also seen in melanoma and bladder carcinoma. CDDP combined with vinblastine and bleomycin resulted in a 39% complete response rate in testicular germ cell tumors. All complete responders and ten patients treated in an adjuvant fashion remain alive and disease-free. Failures to achieve a complete response were associated with bulky extrapulmonary disease, pulmonary disease greater than 2.5 cm in diameter, and past failure to respond to vinblastine and bleomycin. CDDP combination regimens for acute leukemia and for melanoma were of little value. Combination chemotherapy for head and neck cancer showed activity, including a complete response in one of two patients with nasopharyngeal lymphoepithelioma.
D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy
D002945:Cisplatin